1	Retrospective feasibility study of Mycobacterium tuberculosis modified
2	lipoprotein as a potential biomarker for TB detection in children
3	
4	Xinxin Yang, ^{a,b} Matthew F. Wipperman, ^{a,c} Sharon Nachman, ^d Nicole S. Sampson ^{a,#}
5	
6	^a Department of Chemistry, Stony Brook University, Stony Brook, NY 11794-3400
7	^b Chronus Pharmaceuticals, Inc., 25 Health Sciences Drive, Stony Brook, NY 11790
8	^c Current address: Clinical and Translational Science Center, Weill Cornell Medicine,
9	New York, NY 10065
10	^d Department of Pediatrics, Renaissance School of Medicine, Stony Brook University,
11	Stony Brook, NY 11794-3400
12	
13	Running title: Retrospective Mtb lipoprotein biomarker in children
14	
15	*Corresponding author: nicole.sampson@stonybrook.edu
16	
17	Abstract
18	Background: Current TB diagnostic methods available have been developed for adults
19	and development efforts have neglected the differences in disease and sampling that
20	occur between adults and children. Diagnostic challenges are even greater in HIV co-
21	infected children and infants.
22	Methods and results: We established a sandwich ELISA assay to detect
23	Mycobacterium tuberculosis modified lipoprotein (TLP) ex vivo in plasma. The study

- 24 population contains plasma samples from 21 patients with active TB and 24 control
- 25 samples with no TB, collected in the International Maternal Pediatric Adolescent AIDS
- 26 Clinical Trails (IMPAACT) P1041 study. Retrospective analysis was performed and the
- 27 result demonstrate that TLP level is associated with TB disease.
- 28 **Conclusions:** Plasma levels of TLP associate with active TB disease in HIV positive
- 29 subjects and can be used as an indicator for TB detection in children.
- 30

31 Keywords

- 32 Childhood TB, HIV co-infection, diagnosis, sandwich ELISA, lipoprotein, low-density
- 33 lipoprotein, apoB, biomarker

34 BACKGROUND

35 Childhood TB is estimated to contribute 12% of the disease burden, with 36 approximately 10 million cases in 2019 worldwide [1]. Existing gold-standard diagnostic 37 culture tools fail to confirm TB in most children, who typically have low bacterial counts 38 and cannot produce sputum like adults. Diagnostic challenges are great in HIV co-39 infected children and infants [2], where the clinical presentation of pulmonary TB may 40 be non-specific [3], acute [4, 5], and chest radiographs may be atypical [2]. Although 41 rates of bacteriological confirmation appear similar in HIV-infected and uninfected 42 children [6], diagnostic delay and HIV-related immune pathology contribute to higher 43 rates of TB disease progression with increased disease severity, morbidity, and 44 mortality [7-10]. Infants, young children, and HIV-infected children are at increased risk 45 of developing TB following infection and of disseminated or severe disease, including 46 TB meningitis [11]. Because TB in children is typically paucibacillary, even if a sputum 47 sample or gastric aspirate is obtained, the utility of PCR based diagnostic methods like 48 GeneXpert is limited. More sensitive and child-friendly diagnostic tools are urgently 49 needed to diagnose TB in children [12].

Mycobacterium tuberculosis (*Mtb*) is an intracellular pathogen that is capable of surviving and replicating within macrophages, the frontline of the innate host defense, and has evolved multiple mechanisms to escape these immune cells [13]. One of the immune evasion strategies of *Mtb* is the deregulation of lipid metabolism, leading to the formation of foamy macrophages (FM), a hallmark of granulomata in tuberculosis lesions [14]. However, only pathogenic mycobacterial strains including *M. tuberculosis* [15], *M. avium, M. abscessus, or M. bovis*, but not non-pathogenic mycobacterial

57 strains, like *M. smegmatis*, induce foam cell formation upon infection [16, 17]. Foam 58 cells are associated with chronic inflammation in many metabolic diseases and certain 59 cancers besides infectious diseases [18, 19]. For example, foamy macrophages are 60 critical to the initial formation, development, and instability of atherosclerotic plaques 61 and are therefore therapeutic targets in atherosclerosis. Foam cell formation is induced 62 primarily by malondialdehyde-modified low density lipoprotein (MDA-LDL) and not by 63 native or extensively oxidized LDL in atherosclerosis [20]. Elevated plasma levels of 64 MDA-LDL in patients are associated with acute coronary syndromes and are used as 65 diagnostic tools clinically [21].

In this study we identified human lipoprotein modification specific to exposure to *Mtb.* The pathogen modified host lipoprotein, TLP, is detectable ex vivo in plasma using a sandwich ELISA assay. We further evaluated the association between the presence of TLP and TB disease status in children.

70

71 METHODS

72 Preparation of malondialdehyde-conjugated LDL (MDA-LDL) [20] and Mtb-73 modified lipoprotein (TLP). HepG2 human liver cells (ATCC HB-8065) were grown to 74 80% confluence in HepG2 growth media (DMEM, 10% fetal bovine serum, 20 mM L-75 glutamine, 100 U/mL penicillin, 100 µg/mL streptomycin, and 10 mM HEPES). Cells 76 were grown for 4-5 days and culture supernatants were then harvested and 77 concentrated. LDL particles were separated by density gradient ultracentrifugation and desalted by ultrafiltration through a 100-kDa molecular weight filter. MDA-LDL was 78 79 prepared by incubation 2 mg protein/mL of LDL with 2 µM acrolein at 37 °C for 24 h

under nitrogen atmosphere. *Mycobacterium tuberculosis* was cultured in Middlebrook
7H9 (broth) supplemented with 0.2% glycerol, 0.5% BSA, 0.08% NaCl, 0.05% (v/v)
tyloxapol to OD~0.7. LDL was added and the culture was incubated at 37 °C for 7 days.
TLP was isolated from the culture supernatant, concentrated and washed with PBS.

84 Agarose gel electrophoresis and western blot analysis. Agarose gel 85 electrophoresis was performed in 0.06 M barbital buffer (pH 8.6). The gel was 0.8% and 86 stained with Sudan Red 7B. Lipoproteins were separated on a 6% sodium dodecyl 87 sulfate polyacrylamide gel electrophoresis (SDS-PAGE), proteins were transferred to a 88 PVDF membrane and immunoblotted with specific antibodies. The primary antibodies 89 used for western blot were monoclonal anti-LDL (MDA oxidized) antibody (Abcam) and 90 polyclonal anti-apoB Ab (H-300, Santa Cruz). Membranes were treated with anti-mouse, 91 or anti-rabbit IgG HRP conjugates as secondary antibodies.

92 THP-1 macrophage preparation and treatment. THP-1 cells (ATCC TIB-202) 93 were maintained in RPMI-1640 medium containing heat-inactivated 10% fetal bovine 94 serum (FBS), 0.05 mM 2-mercaptoethanol, 100 U/mL penicillin and 100 mg/mL 95 streptomycin (RPMI complete medium). The cells were plated into 6-well plates 96 containing coverslips (1.5×10⁶ /well), treated with phorbol 12-myristate 13-acetate 97 (PMA, 150 nM) in RPMI complete media. Media was replaced with fresh RPMI 98 complete media at 48 hours after plating. At 72 hours after media change, THP-1 99 macrophages were treated with LDL, MDA-LDL and TLP at 200 µg/mL in PBS for 24 100 hours. All cells were incubated in a humid atmosphere at 37°C with 95% air and 5% 101 CO₂.

Lipid body staining and immunostaining. Following lipoprotein treatment, macrophages were washed with PBS and fixed with 4% paraformaldehyde at room temperature for 30 minutes. Cells were stained with Oil Red O solution for 20 minutes at room temperature. The slides were then counterstained with haematoxylin and observed under an inverted microscope (Zeiss Axiovert 200M). Percent foam cell formation was quantified by counting stained versus total cells in 10 fields.

108 Generation of anti-TLP antibodies [22, 23]. Monoclonal antibodies against 109 TLP were identified utilizing Human Combinatorial Antibody Library (HuCAL, Bio-Rad 110 AbD Serotec GmbH). The HuCAL phage display library was depleted of antibodies that 111 recognize intact LDL. The depleted library was panned for three rounds of binding, 112 elution, and amplification to isolate antibodies specific for TLP. Binding of anti-TLP 113 antibodies to control antigens including BSA, HSA, N1-CD33-His6 and intact LDL, was 114 checked by indirect ELISA assays, with anti-TLP antibodies as primary antibodies and 115 an anti-Fab-AP conjugate (Bio-Rad) as a secondary antibody.

116 Sandwich ELISA assay. Briefly, 96 well plates were coated overnight at 4°C 117 with 5 µg/mL capture antibody (AbD28580, amino acid sequence shown in Table S2) in 118 phosphate buffered saline (PBS). Plates were washed with PBS containing 0.05% 119 Tween-20 (PBST) 3 times, blocked with 3% BSA in PBST for 1 hour at room 120 temperature. Then serial dilutions of standards and test samples in HISPEC assay 121 diluent (Bio-Rad) were loaded and allowed to react for 2 hours at room temperature. 122 Plates were then washed 3 times with PBST and treated with 2 µg/mL of HRP 123 conjugated detection antibody (AbD28582) in HISPEC assay diluent for 1 hour at room 124 temperature. After washing 6 times with PBST, the plates were developed with

QuantaBlu fluorogenic peroxidase substrate kit (Thermo Scientific) for 30 min at room
 temperature. Fluorescence was recorded (ex. 320 ± 25nm, em. 430 ± 35nm).


127 Subjects and samples. Retrospective analysis was performed on a total of 45 128 plasma samples from International Maternal Pediatric Adolescent AIDS Clinical Trails 129 (IMPAACT) P1041 [24, 25]. P1041 was a Phase II/ III, randomized, double-blind, 130 placebo-controlled clinical trial to evaluate the efficacy of isoniazid prophylaxis on TB 131 disease and latent *Mtb* infection free survival in HIV-infected and HIV-exposed, but 132 uninfected infants up to 192 weeks of follow up [25, 26]. Samples include 24 with noTB 133 and 21 with TBDIS, all HIV infected. Patients without Mtb infection were categorized as 134 noTB; patients with a positive tuberculin skin test but lacking any clinical, radiographic 135 or laboratory evidence of disease caused by Mtb were categorized as latent TB 136 infection (LTBI); and patients presenting clinical, radiographic or laboratory evidence of 137 disease caused by *Mtb* were categorized as TBDIS. Plasma samples were collected, 138 frozen and thawed before use.


Statistical Analysis. Categorical variables were compared using t-student test,
whenever appropriate. Non-parametric tests (Mann-Whitney) were used for nonnormally distributed variables. Assay accuracy, including 95% confidence intervals, was
assessed using sensitivity, specificity, predictive values and area under the ROC in the
TB and non-TB groups. Statistical calculations were performed with GraphPad
Prism® Software.

145

146 **RESULTS**

Mtb modified lipoprotein (TLP) is different from MDA-LDL. We purified and 147 148 treated native LDL with Mycobacterium tuberculosis in vitro to obtain Mtb modified 149 lipoprotein (TLP). Decreased mobility of TLP in agarose electrophoresis indicates that 150 TLP is more positively charged than native LDL (Figure 1A). In contrast, MDA-LDL, one 151 of the end products of lipid peroxidation, is more negatively charged than native LDL 152 [20]. The increased size of TLP compared to native LDL was also confirmed by dynamic 153 light scattering analysis (Table S1). Furthermore, TLP is recognized by anti-154 apolipoprotein B (apoB) antibodies but not anti-MDA-LDL antibodies, indicating TLP 155 does not contain a malondialdehyde-modified apoB derivative (Figure 1B). We 156 demonstrate that LDL is altered in the presence of *Mtb*, and the resulting TLP is distinct 157 from the typical atherosclerotic species malondialdehyde-modified LDL (MDA-LDL) 158 present in human blood [27].





- 164 showing TLP is recognized by anti- apolipoprotein B (apoB) antibodies (top) but not
- anti- MDA-LDL antibodies (bottom). Images of the entire gel and blots are in Figure S1.

167 Mtb modified LDL induces lipid body accumulation in macrophages. The 168 induction of foamy macrophages have been reported as hallmarks in many pathologies 169 associated with chronic proinflammatory stimuli including atherosclerosis [15]. It has 170 also been reported that Mtb lipids induce the formation of giant multinuclear 171 macrophages [28]. We therefore used foamy macrophage formation as a tool to assess 172 the bioactive components that trigger a tissue response similar to granuloma formation 173 in TB. Lipid bodies were stained with Oil red O. The buffer control showed no 174 accumulation of lipid bodies and the cells remained rounded (Figure 2A). LDL treated macrophage showed some lipid accumulation, with a commensurate increase in cell 175 176 size (Figure 2B). In contrast, MDA-LDL, commonly associated with atherosclerosis, 177 treated macrophages exhibited more extensive accumulation of lipid bodies than the 178 LDL treated macrophages. These macrophage phenotypes are consistent with previous 179 reports of in vitro foamy macrophage formation [20, 29]. Most importantly, TLP treated 180 macrophages had extensive lipid body accumulation per cell compared to macrophages 181 treated with other LDLs (Figure 2 and S2B). Moreover, the TLP-treated macrophage 182 morphology was distinct from other samples. The majority of the TLP-treated 183 macrophages became multinucleated (Figure 2D and S2A) and developed long 184 filopodia consistent with cell migration or exocytosis. Thus, we hypothesize that the 185 modified LDL is detectable in vivo to serve as a biomarker for TB disease, and an 186 antibody specific for recognition of TLP is an *Mtb*-specific indicator of infection and 187 progression to (active) TB disease.





Figure 2. TLP induces lipid body accumulation in macrophages. Microscopic
images of Oil Red O-hematoxylin stained THP-1 macrophage culture treated with PBS
control (A), LDL (B), MDA-LDL (C) and TLP (D) at 200 µg/mL for 2 days.

195

196 Anti-TLP monoclonal antibodies were generated and a TLP Sandwich ELISA 197 assay was established. We generated 13 anti-TLP monoclonal antibodies (Fad-A-FH, 198 bivalent Fab-bacterial alkaline phosphatase fusion antibody followed by FLAG[®] and His6-199 tag) from the Human Combinatorial Antibody Library (HuCAL, Bio-Rad AbD Serotec 200 GmbH) using in vitro selection and counter selection [22, 23]. HuCAL is a phage display 201 library containing highly specific, fully human monoclonal antibodies, with DNA sequence 202 encoded for each antibody fragment. The HuCAL phage display library was depleted of 203 antibodies that recognize LDL (Figure S3). The depleted library was panned for three 204 rounds of binding, elution, and amplification to isolate antibodies specific for TLP. Among 205 the antibody hits selected, 13 antibodies were identified as unique by DNA sequencing. 206 These antibodies were produced heterologously for further development. The cross-207 reactivity with native LDL, human serum albumin, bovine serum albumin, and His₆ affinity 208 tag was determined in an indirect ELISA format. Eight antibodies showed a specific signal 209 for TLP at least 4-fold above native LDL background (Figure S3). We tested pairwise

combinations of antibodies to identify antibody pairs that have non-overlapping epitopes suitable for use in a sandwich ELISA (Figure S4A). 5 sandwich pairs were identified with good signal over background and the assay conditions were optimized for the best pair, AbD28582 and AbD28580 (amino acid sequence shown in Table S2). We established the linear response of the sandwich ELISA (Figure S4B) to antigen spiked into pediatric plasma. TLP is specifically detected at >=4ppm in the presence of plasma LDL, which is around 10⁶ ng/mL [30].

217 Levels of TLP are increased in patients with active TB compared to no TB 218 controls. We assayed stored plasma samples from the HIV IMPAACT P1041 trial for 219 the presence of TLP. The median plasma levels of TLP was 494 ng/mL in control 220 subjects, and 2.7 fold higher in active TB subjects (Figure 3A). The difference between 221 control subjects and active TB subjects is significant (p<0.001). The receiver operating 222 characteristic (ROC) analysis describes the relationship between the sensitivity and 223 specificity at any cut-off values. An ROC curve of TLP concentration for active TB 224 versus control subjects is presented in Figure 3B. The area under the ROC curve (AUC) 225 is 0.86 (95% CI=0.75-0.97, p<0.0001). An optimal cutoff of 1064 ng/mL rendered 71% 226 sensitivity and 88% specificity. Alternatively, a cutoff of 1230 ng/mL provided 57% 227 sensitivity and of 96% specificity.



231 Figure 3. Retrospective analysis of P1041 HIV positive plasma samples. (A)

Plasma levels of TLP in HIV positive subjects clinically diagnosed probably having active stage tuberculosis disease (TB) and not having TB (noTB). Individual patients are depicted as dots with group mean. The dashed line represents the detection limit of the assay. *** p<0.001. (B) ROC curve of TLP concentration for active TB versus control subjects of HIV positive patients. AUC, area under curve. The dashed line represents the no-discrimination line from the left bottom to the top right corners.

238

We also monitored apoB levels, i.e., LDL levels, of all the samples using Human 239 240 apoB ELISA kits (ab190806, Abcam) and found there was no linear correlation between 241 TLP and apoB levels (Figure S6A), suggesting that plasma LDL fluctuation does not 242 interfere with TLP detection. There is a weak correlation between TLP levels and time 243 before or after diagnosis (Figure S6B). The samples collected before diagnosis may represent disease progression from no infection or infection but without clinical signs of 244 245 disease to outward manifestation of disease. Samples collected after diagnosis may 246 represent a mixed outcome of disease progression and anti- tubercular treatment. We

247 do not have additional sample sets to demonstrate if anti-tubercular treatment affects 248 TLP levels. However, the discrimination of TLP levels between control subjects and 249 active TB subjects (post diagnosis with treatment less than 40 weeks) was improved 250 with the exclusion of samples collected after 40 weeks of treatment (p<0.0001), which 251 may represent patients clear of TB (Figure S6). ROC (Receiver operating characteristic) 252 analysis provided an AUC (area under the ROC curve) of 0.88 (95% CI=0.76-0.99, 253 p<0.0001). An optimal cutoff of 632 ng/mL gave 67% sensitivity and 93% specificity. 254 The results provide further evidence that TLP levels are associated with active TB 255 disease. Overall, the results clearly highlight the potential of TLP as a biomarker in the 256 diagnosis of active TB in HIV positive children.

257

258 DISCUSSION AND CONCLUSIONS

259 The wide spectrum of disease observed in children, and the non-specific signs and 260 symptoms especially in young and HIV+ children, contribute to diagnostic delay and 261 missed opportunities to detect TB, which in turn, favors TB disease progression and poor 262 treatment outcomes. There is urgent need to search for a "Rapid Non-sputum-based 263 Biomarker Test for Tuberculosis Detection" [12] .Most of the biomarkers currently studied are host-derived biomarkers including metabolites and cytokines,^[31, 32] the levels of which 264 265 can be affected by many confounding factors. On the other hand, Mtb products can be 266 detected directly in blood, sputum or urine, and are increasingly being used for diagnosis.^[33] We have characterized a unique biomolecule, *Mtb* modified lipoprotein, 267 268 which results from a combination of host and *Mtb* pathogen activity. Functionally, TLP 269 increases the flux of lipid into activated macrophages, thereby stimulating their conversion

into foamy multi-nucleated macrophages. The TLP-stimulated macrophages accumulate lipid bodies but have a distinct phenotype from MDA-LDL-stimulated macrophages (Figure 2). We reason that detection of this biomolecule in patient plasma may withstand the heterogeneity associated with variations derived from host and be pathogen or disease specific. Thus, TLP detection may be used as TB diagnosis in young children.

275 The lipoprotein modification can take place in macrophages in contact with M. 276 tuberculosis. There are also reports demonstrating that extracellular vesicles carrying 277 bacterial components are released from infected macrophages and circulated beyond 278 the site of infection [34], where host lipoproteins could be modified via contact with the 279 extracellular vesicles. In addition, the intracellular bacilli are able to avoid killing by 280 escaping phagosome-lysosome fusion. In certain individuals, especially children below 281 5 years of age and immunosuppressed subjects, the extracellular bacilli may disperse to 282 distant metastatic sites via lymphatics and the bloodstream [35], where host lipoproteins 283 may be modified by direct contact with *M. tuberculosis*. Our data demonstrate that the 284 modified lipoprotein in the present study is distinct from other commonly recognized 285 disease associated LDLs, which are typically negatively charged and smaller in particle 286 size compared to native LDL [36].

The present study established a rapid, non-invasive, and robust sandwich ELISA assay for the detection of a novel biomolecule TLP in plasma. We demonstrate that plasma levels of TLP are significantly distinguishable in HIV positive subjects with active TB disease compared to no TB controls (Figure 3). The significant elevation of plasma levels of TLP in HIV positive subjects with active TB disease suggests the detection of TLP associate with TB active disease in HIV positive subjects. The AUC value of 0.86

293 evidenced the diagnostic value of TLP for TB detection in child. The target product profiles 294 (TPP) adopted by the World Health Organization (WHO) in 2015 for a "Rapid Non-295 sputum-based Biomarker Test for Tuberculosis Detection" is a diagnostic sensitivity $\geq 66\%$ 296 for microbiologically confirmed pediatric TB and 98% specificity for a pediatric test [12]. 297 The TPP proposed sensitivity is similar to the sensitivity of the Xpert MTB/RIF assay in 298 microbiologically confirmed samples. Our assay renders 57% sensitivity and 96% 299 specificity, which has the potential to meet the WHO TPP for detection of active TB in 300 children, given the highly heterogenous population of P1041 samples, with respect to the 301 bacteriological and clinical status.

302 Samples used in our study were obtained from IMPAACT P1041 clinical trial. The 303 accuracy of TB diagnosis for the P1041 trial samples is not known due to the absence of 304 good pediatric TB diagnostics. In addition, microbiological confirmation of TB disease was 305 not obtained for any of these patients in the P1041 trial. TB disease subjects used in the 306 present study are patients infected with TB presenting clinical symptoms of disease. The 307 ELISA assays were performed retrospectively and the variance in storage conditions 308 might affect the antigen integrity and therefore the accuracy of the assay. We have 309 insufficient samples to include other clinical characteristics of the patients into data 310 analysis. The clinical characteristics include but not limited to BCG administration, 311 immunosuppression status like CD4 counts, or clinical manifestation of tuberculosis 312 (pulmonary and extra-pulmonary TB). The consideration of those characteristics may help 313 define the limitation of our TLP assay or render improved accuracy with the combination 314 of other clinical factors.

315 We focused on HIV positive subjects in the current study. TB diagnosis is particularly 316 difficult among HIV co-infected individuals who may have atypical, nonspecific clinical 317 presentation, high rates of smear negative disease and high rates of extrapulmonary TB 318 [37]. P1041 samples were obtained from TB endemic settings, therefore patients were 319 typically being diagnosed at more advanced stages than those living in the US. Therefore, 320 the heterogenous stages of TB disease may contribute to the wide dispersity of TLP levels 321 in TB disease subjects (Figure 3A), which is common among TB diagnostic assays. In 322 addition, the duration of anti-tubercular treatment was not consistent among patients in 323 the present study. Change of LDL modification is a dynamic process and may have the 324 potential to monitor treatment outcome. Although not statistically significant, the slight 325 decrease in the TLP level post diagnosis/ anti-tubercular treatment of 40 weeks may be 326 related to a reduction in microbial load (Figures S6A and S6B). Further studies are 327 required to elucidate the effect of different disease status and/or treatment status on TLP 328 levels in plasma, and to extend our preliminary results to other populations such as HIV 329 negative subjects and adults.

It is a growing notion in the field that a single biomarker will not be sufficient for distinguishing TB status in different patient groups, and multiple biomarkers may be used to increase sensitivity and specificity. Further gains in clinical sensitivity and specificity may be obtained by combining the current assay with other biomarkers or diagnostic tests.

335

336 LIST OF ABBREVIATIONS

337	TB, tuberculosis; Mtb, Mycobacterium tuberculosis; ELISA, enzyme-linked
338	immunosorbent assay; FM, foamy macrophages; MDA-LDL, malondialdehyde-modified
339	low density lipoprotein; TLP, Mycobacterium tuberculosis modified lipoprotein; ROC,
340	receiver operating characteristic; AUC, area under the ROC curve.
341	
342	DECLARATIONS
343	Ethics approval and consent to participate
344	The NIH-IMPAACT Scientific Leadership Group (SLG) reviewed and approved the
345	use of P1041 trial samples under NWCS127. The Wits Health Consortium,
346	University of Witwatersrand, South Africa provided deidentified samples to Stony
347	Brook University for which informed consent had been obtained from a parent
348	and/or legal guardian. The Stony Brook University CORIHS determined the
349	experiments in this manuscript were not human subjects research under either
350	the Common Rule or FDA Regulations.
351	Consent for publication
352	All authors have approved the manuscript for submission.
353	Availability of data and materials
354	The datasets used and/or analysed during the current study are available from
355	the corresponding author on reasonable request.

Competing interests

357	NSS is President and co-owner of Chronus Pharmaceuticals, Inc. XY was an
358	employee of both Chronus Pharmaceuticals, Inc and Stony Brook University. All
359	intellectual property is currently owned by Stony Brook University. SN and MFM
360	have no conflict of interest.
361	Funding
362	Research reported in this publication was supported by the National Heart, Lung,
363	and Blood Institute of the National Institutes of Health under Award Number
364	U01HL127522, and National Institute of Allergy and Infectious Diseases (NIAID)
365	under award number R41AI136071 to Chronus Pharmaceuticals, Inc with a
366	subcontract to Stony Brook University (NSS) and the National Center for
367	Advancing Translational Sciences under award number TL1TR002386 (MFW).
368	Overall support for the International Maternal Pediatric Adolescent AIDS Clinical
369	Trials (IMPAACT) Network was provided by the National Institute of Allergy and
370	Infectious Diseases (NIAID) of the National Institutes of Health (NIH) under Award
371	Numbers UM1AI068632 (IMPAACT LOC), UM1AI068616 (IMPAACT SDMC) and
372	UM1AI106716 (IMPAACT LC), with co-funding from the Eunice Kennedy Shriver
373	National Institute of Child Health and Human Development (NICHD) and the
374	National Institute of Mental Health (NIMH). The content is solely the
375	responsibility of the authors and does not necessarily represent the official views
376	of the NIH.

377		Authors' contributions
378		SN, MFW, XY, NSS conceived the experiments
379		SN, MFW, obtained sample resource
380		XY performed the experiments
381		XY, NSS wrote the main manuscript text
382		XY prepared all figures
383		All authors reviewed the manuscript
384		Acknowledgements
385		We thank Guannan Chen for help with initial LDL purification experiments.
386		
387	REF	ERENCES
388	1.	WHO.2020.Globaltuberculosisreport
389		https://apps.who.int/iris/bitstream/handle/10665/336069/9789240013131-eng.pdf
390		Accessed 16 March 2021.
391	2.	Cotton MF, Schaaf HS, Hesseling AC, Madhi SA: HIV and childhood tuberculosis: the way
392		forward. The international journal of tuberculosis and lung disease : the official journal of the
393		International Union against Tuberculosis and Lung Disease 2004, 8 (5):675-682.
394	3.	Marais BJ, Gie RP, Obihara CC, Hesseling AC, Schaaf HS, Beyers N: Well defined symptoms
395		are of value in the diagnosis of childhood pulmonary tuberculosis. Archives of disease in
396		childhood 2005, 90 (11):1162-1165.
397	4.	Moore DP, Klugman KP, Madhi SA: Role of Streptococcus pneumoniae in hospitalization
398		for acute community-acquired pneumonia associated with culture-confirmed

- 399 *Mycobacterium tuberculosis* in children: a pneumococcal conjugate vaccine probe
 400 study. The Pediatric infectious disease journal 2010, 29(12):1099-1004.
- 401 5. Zar HJ, Tannenbaum E, Apolles P, Roux P, Hanslo D, Hussey G: Sputum induction for the
 402 diagnosis of pulmonary tuberculosis in infants and young children in an urban setting
 403 in South Africa. Archives of disease in childhood 2000, 82(4):305-308.
- Walters E, Cotton MF, Rabie H, Schaaf HS, Walters LO, Marais BJ: Clinical presentation and
 outcome of tuberculosis in human immunodeficiency virus infected children on anti retroviral therapy. *BMC pediatrics* 2008, 8:1.
- Jeena PM, Mitha T, Bamber S, Wesley A, Coutsoudis A, Coovadia HM: Effects of the human
 immunodeficiency virus on tuberculosis in children. *Tubercle and lung disease : the*official journal of the International Union against Tuberculosis and Lung Disease 1996,
 77(5):437-443.
- 411 8. Schaaf HS, Gie RP, Beyers N, Smuts N, Donald PR: Tuberculosis in infants less than 3
 412 months of age. Archives of disease in childhood 1993, 69(3):371-374.
- Jeena PM, Pillay P, Pillay T, Coovadia HM: Impact of HIV-1 co-infection on presentation
 and hospital-related mortality in children with culture proven pulmonary
 tuberculosis in Durban, South Africa. The international journal of tuberculosis and lung
 disease : the official journal of the International Union against Tuberculosis and Lung Disease
 2002, 6(8):672-678.
- Madhi SA, Huebner RE, Doedens L, Aduc T, Wesley D, Cooper PA: HIV-1 co-infection in
 children hospitalised with tuberculosis in South Africa. The international journal of
 tuberculosis and lung disease : the official journal of the International Union against
 Tuberculosis and Lung Disease 2000, 4(5):448-454.
- 422 11. Marais BJ, Gie RP, Schaaf HS, Hesseling AC, Obihara CC, Starke JJ, Enarson DA, Donald PR,
 423 Beyers N: The natural history of childhood intra-thoracic tuberculosis: a critical review

425

426

of literature from the pre-chemotherapy era. The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease 2004, **8**(4):392-402.

- 427 12. Denkinger CM, Kik SV, Cirillo DM, Casenghi M, Shinnick T, Weyer K, Gilpin C, Boehme CC,
 428 Schito M, Kimerling M *et al*: Defining the needs for next generation assays for
 429 tuberculosis. *J Infect Dis* 2015, 211 Suppl 2:S29-38.
- 430 13. Abdalla AE, Ejaz H, Mahjoob MO, Alameen AAM, Abosalif KOA, Elamir MYM, Mousa MA:
 431 Intelligent Mechanisms of Macrophage Apoptosis Subversion by Mycobacterium.
 432 Pathogens 2020, 9(3).
- 433 14. Genoula M, Marin Franco JL, Dupont M, Kviatcovsky D, Milillo A, Schierloh P, Morana EJ, Poggi
 434 S, Palmero D, Mata-Espinosa D *et al*: Formation of Foamy Macrophages by Tuberculous
 435 Pleural Effusions Is Triggered by the Interleukin-10/Signal Transducer and Activator
 436 of Transcription 3 Axis through ACAT Upregulation. *Front Immunol* 2018, 9:459.
- 437 15. Russell DG, Cardona PJ, Kim MJ, Allain S, Altare F: Foamy macrophages and the progression
 438 of the human tuberculosis granuloma. *Nat Immunol* 2009, **10**(9):943-948.
- Viljoen A, Blaise M, de Chastellier C, Kremer L: MAB_3551c encodes the primary
 triacylglycerol synthase involved in lipid accumulation in Mycobacterium abscessus.
 Mol Microbiol 2016, 102(4):611-627.
- 442 17. Caire-Brandli I, Papadopoulos A, Malaga W, Marais D, Canaan S, Thilo L, de Chastellier C:
 443 Reversible lipid accumulation and associated division arrest of Mycobacterium avium
 444 in lipoprotein-induced foamy macrophages may resemble key events during latency
 445 and reactivation of tuberculosis. *Infect Immun* 2014, 82(2):476-490.
- 446 18. Guerrini V, Gennaro ML: Foam Cells: One Size Doesn't Fit All. Trends Immunol 2019,
 447 40(12):1163-1179.

- 448 19. Agarwal P, Combes TW, Shojaee-Moradie F, Fielding B, Gordon S, Mizrahi V, Martinez FO:
 449 Foam Cells Control Mycobacterium tuberculosis Infection. *Front Microbiol* 2020, 11:1394.
 450 20. Watanabe K, Nakazato Y, Saiki R, Igarashi K, Kitada M, Ishii I: Acrolein-conjugated low451 density lipoprotein induces macrophage foam cell formation. *Atherosclerosis* 2013,
 452 227(1):51-57.
- 453 21. Holvoet P, Vanhaecke J, Janssens S, Van de Werf F, Collen D: Oxidized LDL and
 454 malondialdehyde-modified LDL in patients with acute coronary syndromes and stable
 455 coronary artery disease. *Circulation* 1998, 98(15):1487-1494.
- Knappik A, Ge L, Honegger A, Pack P, Fischer M, Wellnhofer G, Hoess A, Wolle J, Pluckthun A,
 Virnekas B: Fully synthetic human combinatorial antibody libraries (HuCAL) based on
 modular consensus frameworks and CDRs randomized with trinucleotides. *J Mol Biol*2000, 296(1):57-86.
- Prassler J, Thiel S, Pracht C, Polzer A, Peters S, Bauer M, Norenberg S, Stark Y, Kolln J, Popp A *et al*: HuCAL PLATINUM, a synthetic Fab library optimized for sequence diversity and
 superior performance in mammalian expression systems. J Mol Biol 2011, 413(1):261278.
- 464 24. Madhi SA, Nachman S, Violari A, Kim S, Cotton MF, Bobat R, Jean-Philippe P, McSherry G,
 465 Mitchell C, Team PS: Primary isoniazid prophylaxis against tuberculosis in HIV-exposed
 466 children. *The New England journal of medicine* 2011, 365(1):21-31.
- 46725.A randomized, double blind, placebo controlled trial to determine the efficacy of468isoniazid (INH) in preventing tuberculosis disease and latent tuberculosis infection469among infants with perinatal exposure to HIV.470[https://impaactnetwork.org/DocFiles/P1041/P1041V2_11Jul07.pdf]
- 471 26. Gupta A, Montepiedra G, Gupte A, Zeldow B, Jubulis J, Detrick B, Violari A, Madhi S, Bobat R,
 472 Cotton M *et al*: Low Vitamin-D Levels Combined with PKP3-SIGIRR-TMEM16J Host

- 473 Variants Is Associated with Tuberculosis and Death in HIV-Infected and -Exposed
 474 Infants. *PloS one* 2016, **11**(2):e0148649.
- Yoshida M, Higashi K, Kobayashi E, Saeki N, Wakui K, Kusaka T, Takizawa H, Kashiwado K,
 Suzuki N, Fukuda K *et al*: Correlation between images of silent brain infarction, carotid
 atherosclerosis and white matter hyperintensity, and plasma levels of acrolein, IL-6
 and CRP. *Atherosclerosis* 2010, 211(2):475-479.
- 479 28. Puissegur MP, Lay G, Gilleron M, Botella L, Nigou J, Marrakchi H, Mari B, Duteyrat JL, Guerardel

480 Y, Kremer L *et al*: **Mycobacterial lipomannan induces granuloma macrophage fusion via**

- 481 a TLR2-dependent, ADAM9- and beta1 integrin-mediated pathway. J Immunol 2007,
 482 178(5):3161-3169.
- 483 29. Nezami N, Ghorbanihaghjo A, Rashtchizadeh N, Argani H, Tafrishinejad A, Ghorashi S,
 484 Hajhosseini B: Atherogenic changes of low-density lipoprotein susceptibility to
 485 oxidation, and antioxidant enzymes in pulmonary tuberculosis. *Atherosclerosis* 2011,
 486 217(1):268-273.
- 30. Sacks FM, Moye LA, Davis BR, Cole TG, Rouleau JL, Nash DT, Pfeffer MA, Braunwald E:
 Relationship between plasma LDL concentrations during treatment with pravastatin
 and recurrent coronary events in the cholesterol and recurrent events trial. *Circulation*1998, 97(15):1446-1452.
- 491 31. Weiner J, Kaufmann SH: Recent advances towards tuberculosis control: vaccines and
 492 biomarkers. *Journal of internal medicine* 2014.
- 493 32. Walzl G, Ronacher K, Hanekom W, Scriba TJ, Zumla A: Immunological biomarkers of
 494 tuberculosis. *Nature reviews Immunology* 2011, 11(5):343-354.
- Goletti D, Lee MR, Wang JY, Walter N, Ottenhoff THM: Update on tuberculosis biomarkers:
 from correlates of risk, to correlates of active disease and of cure from disease. *Respirology* 2018, 23(5):455-466.

- Athman JJ, Wang Y, McDonald DJ, Boom WH, Harding CV, Wearsch PA: Bacterial membrane
 vesicles mediate the release of Mycobacterium tuberculosis lipoglycans and
 lipoproteins from infected macrophages. *J Immunol* 2015, **195**(3):1044-1053.
- 50135.Grosset J: Mycobacterium tuberculosis in the extracellular compartment: an502underestimated adversary. Antimicrob Agents Chemother 2003, 47(3):833-836.
- 503 36. Orekhov AN: LDL and foam cell formation as the basis of atherogenesis. *Curr Opin Lipidol*504 2018, 29(4):279-284.
- 505 37. Scott L, da Silva P, Boehme CC, Stevens W, Gilpin CM: **Diagnosis of opportunistic infections**:
- 506 HIV co-infections tuberculosis. *Curr Opin HIV AIDS* 2017, **12**(2):129-138.